Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 déc. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
10 nov. 2022 16h05 HE
|
Oyster Point Pharma, Inc.
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3’22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by...
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
07 nov. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per SharePRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) --...
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
02 nov. 2022 16h02 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 nov. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
27 sept. 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 sept. 2022 17h36 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
25 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
17 août 2022 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...